Actuate Therapeutics (ACTU) Competitors

$3.07 +0.12 (+4.07%)

Closing price 04:00 PM Eastern

Extended Trading

$3.08 +0.01 (+0.16%)

As of 04:45 PM Eastern

ACTU vs. ELDN, PLYX, ALEC, NLTX, and CCCC

Should you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Eledon Pharmaceuticals (ELDN), Polaryx Therapeutics (PLYX), Alector (ALEC), Neoleukin Therapeutics (NLTX), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry.

How does Actuate Therapeutics compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

: Eledon Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Actuate Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
: 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: Eledon Pharmaceuticals' return on equity of -85.61% beat Actuate Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Eledon Pharmaceuticals N/A -85.61% -31.93%
Actuate Therapeutics N/A -799.68% -205.80%
: In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 1 mentions for Eledon Pharmaceuticals and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.97 beat Eledon Pharmaceuticals' score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Eledon Pharmaceuticals Neutral
Actuate Therapeutics Positive
: Eledon Pharmaceuticals currently has a consensus target price of $9.67, indicating a potential upside of 155.06%. Actuate Therapeutics has a consensus target price of $17.50, indicating a potential upside of 470.03%. Given Actuate Therapeutics' higher probable upside, analysts clearly believe Actuate Therapeutics is more favorable than Eledon Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eledon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
Actuate Therapeutics
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eledon Pharmaceuticals N/A N/A -$45.62M -$0.52 N/A
Actuate Therapeutics N/A N/A -$22.23M -$1.05 N/A

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-85.61%	-31.93%
Actuate Therapeutics	N/A	-799.68%	-205.80%

Company	Overall Sentiment
Eledon Pharmaceuticals	Neutral
Actuate Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.52	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$1.05	N/A

Summary

Eledon Pharmaceuticals beats Actuate Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to Polaryx Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Actuate Therapeutics N/A N/A -$22.23M -$1.05 N/A
Polaryx Therapeutics N/A N/A N/A N/A N/A
: Actuate Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 470.03%. Polaryx Therapeutics has a consensus target price of $10.00, indicating a potential upside of 120.26%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Actuate Therapeutics is more favorable than Polaryx Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actuate Therapeutics
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
Polaryx Therapeutics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Polaryx Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Actuate Therapeutics N/A -799.68% -205.80%
Polaryx Therapeutics N/A N/A N/A
: In the previous week, Polaryx Therapeutics had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 1 mentions for Polaryx Therapeutics and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.97 beat Polaryx Therapeutics' score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Actuate Therapeutics Positive
Polaryx Therapeutics Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$1.05	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-799.68%	-205.80%
Polaryx Therapeutics	N/A	N/A	N/A

Company	Overall Sentiment
Actuate Therapeutics	Positive
Polaryx Therapeutics	Neutral

Summary

Actuate Therapeutics beats Polaryx Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Actuate Therapeutics compare to Alector?

Actuate Therapeutics (NASDAQ:ACTU) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

: Actuate Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
: Actuate Therapeutics has a net margin of 0.00% compared to Alector's net margin of -679.16%. Alector's return on equity of -224.96% beat Actuate Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Actuate Therapeutics N/A -799.68% -205.80%
Alector -679.16% -224.96% -41.03%
: In the previous week, Alector had 10 more articles in the media than Actuate Therapeutics. MarketBeat recorded 10 mentions for Alector and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.97 beat Alector's score of 0.23 indicating that Actuate Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Actuate Therapeutics Positive
Alector Neutral
: Actuate Therapeutics has higher earnings, but lower revenue than Alector. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Actuate Therapeutics N/A N/A -$22.23M -$1.05 N/A
Alector $21.05M 13.56 -$142.93M -$1.39 N/A
: 85.8% of Alector shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 9.7% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Actuate Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 470.03%. Alector has a consensus target price of $3.63, indicating a potential upside of 41.05%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Actuate Therapeutics is more favorable than Alector.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actuate Therapeutics
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
Alector
2 Sell rating(s)

3 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.13

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-799.68%	-205.80%
Alector	-679.16%	-224.96%	-41.03%

Company	Overall Sentiment
Actuate Therapeutics	Positive
Alector	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$1.05	N/A
Alector	$21.05M	13.56	-$142.93M	-$1.39	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Actuate Therapeutics beats Alector on 8 of the 15 factors compared between the two stocks.

How does Actuate Therapeutics compare to Neoleukin Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

: Actuate Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
: Neoleukin Therapeutics' return on equity of -37.22% beat Actuate Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Actuate Therapeutics N/A -799.68% -205.80%
Neoleukin Therapeutics N/A -37.22% -30.91%
: In the previous week, Neoleukin Therapeutics had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 1 mentions for Neoleukin Therapeutics and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.97 beat Neoleukin Therapeutics' score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Actuate Therapeutics Positive
Neoleukin Therapeutics Neutral
: Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Actuate Therapeutics N/A N/A -$22.23M -$1.05 N/A
Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A
: 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Actuate Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 470.03%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Actuate Therapeutics is more favorable than Neoleukin Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actuate Therapeutics
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
Neoleukin Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-799.68%	-205.80%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Company	Overall Sentiment
Actuate Therapeutics	Positive
Neoleukin Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$1.05	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Actuate Therapeutics beats Neoleukin Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

: C4 Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Comparatively, Actuate Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
: 78.8% of C4 Therapeutics shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: C4 Therapeutics presently has a consensus target price of $7.75, indicating a potential upside of 160.94%. Actuate Therapeutics has a consensus target price of $17.50, indicating a potential upside of 470.03%. Given Actuate Therapeutics' higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than C4 Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C4 Therapeutics
1 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.57
Actuate Therapeutics
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: Actuate Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -292.08%. C4 Therapeutics' return on equity of -53.83% beat Actuate Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
C4 Therapeutics -292.08% -53.83% -33.85%
Actuate Therapeutics N/A -799.68% -205.80%
: In the previous week, C4 Therapeutics had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for C4 Therapeutics and 0 mentions for Actuate Therapeutics. C4 Therapeutics' average media sentiment score of 0.97 equaled Actuate Therapeutics'average media sentiment score.
Company Overall Sentiment
C4 Therapeutics Positive
Actuate Therapeutics Positive
: Actuate Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
C4 Therapeutics $35.95M 8.06 -$104.99M -$1.36 N/A
Actuate Therapeutics N/A N/A -$22.23M -$1.05 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-292.08%	-53.83%	-33.85%
Actuate Therapeutics	N/A	-799.68%	-205.80%

Company	Overall Sentiment
C4 Therapeutics	Positive
Actuate Therapeutics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	8.06	-$104.99M	-$1.36	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$1.05	N/A

Summary

C4 Therapeutics beats Actuate Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Actuate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACTU vs. The Competition

Export

Metric	Actuate Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$72.79M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-2.92	38.85	29.04	28.47
Price / Sales	N/A	155.51	476.61	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	9.03	7.03	9.67	6.67
Net Income	-$22.23M	$23.62M	$3.55B	$332.53M
7 Day Performance	5.86%	3.68%	1.70%	2.01%
1 Month Performance	23.79%	7.16%	5.62%	9.19%
1 Year Performance	-68.96%	67.05%	34.41%	39.59%

Actuate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACTU Actuate Therapeutics	2.2919 of 5 stars	$3.07 +4.1%	$17.50 +470.0%	N/A	$72.79M	N/A	N/A	10
ELDN Eledon Pharmaceuticals	1.2252 of 5 stars	$3.39 -2.7%	$9.67 +185.5%	N/A	$257.36M	N/A	N/A	10	Positive News
PLYX Polaryx Therapeutics	N/A	$5.48 -2.7%	$10.00 +82.6%	N/A	$256.78M	N/A	N/A	11	News Coverage
ALEC Alector	2.4157 of 5 stars	$2.31 -3.3%	$4.17 +80.4%	N/A	$254.60M	$21.05M	N/A	270	Analyst Forecast
NLTX Neoleukin Therapeutics	N/A	$27.03 +0.3%	N/A	N/A	$254.03M	N/A	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACTU) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actuate Therapeutics (ACTU) Competitors

ACTU vs. ELDN, PLYX, ALEC, NLTX, and CCCC

How does Actuate Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Actuate Therapeutics compare to Polaryx Therapeutics?

Summary

How does Actuate Therapeutics compare to Alector?

Summary

How does Actuate Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Actuate Therapeutics compare to C4 Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actuate Therapeutics (ACTU) Competitors

ACTU vs. ELDN, PLYX, ALEC, NLTX, and CCCC

How does Actuate Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Actuate Therapeutics compare to Polaryx Therapeutics?

Summary

How does Actuate Therapeutics compare to Alector?

Summary

How does Actuate Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Actuate Therapeutics compare to C4 Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools